Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells
作者： NAOMI MIYAKE , HIROKI CHIKUMI , MIYAKO TAKATA , MASAKI NAKAMOTO , TADASHI IGISHI
DOI: 10.3892/OR.2012.1855
关键词:
摘要: The mammalian target of rapamycin (mTOR) is a key kinase acting downstream growth factor receptor PI3K and AKT signaling, leading to processes resulting in increased cell size proliferation through translation control. Rapamycin, specific inhibitor mTOR, results predominately G1 cycle arrest control occasionally, type-dependent apoptosis by an unknown mechanism. In this study, we investigated the effect mechanism action on non-small lung cancer (NSCLC) lines with p53 mutations. Cell was evaluated modified MTT assay. apoptotic measured caspase-3 activation flow cytometric analysis Annexin V binding. expression Bcl-2 release cytochrome c from mitochondria were western blotting. We found that induced NSCLC Western blot demonstrated downregulates levels Bcl-2, which leads cytochrome c subsequent caspase cascades. These findings suggest induces p53-independent downregulation mitochondrial pathway as novel antitumor
sci-hub.se 参考文章(35)
D. Aguirre, P. Boya, D. Bellet, S. Faivre, F. Troalen, J. Benard, P. Saulnier, S. Hopkins-Donaldson, U. Zangemeister-Wittke, G. Kroemer, E. Raymond, Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis. ,vol. 9, pp. 797- 805 ,(2004) , 10.1023/B:APPT.0000045781.46314.E2
Myung-Jae Park, Kimihiro Shimizu, Tetsuhiro Nakano, Yong Bum Park, Takashi Kohno, Masachika Tani, Jun Yokota, Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma Cancer Genetics and Cytogenetics. ,vol. 141, pp. 5- 13 ,(2003) , 10.1016/S0165-4608(02)00645-3
Francisco Vega, L. Jeffrey Medeiros, Vasiliki Leventaki, Coralyn Atwell, Jeong Hee Cho-Vega, Ling Tian, Francois-Xavier Claret, George Z. Rassidakis, Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase–Positive Anaplastic Large Cell Lymphoma Cancer Research. ,vol. 66, pp. 6589- 6597 ,(2006) , 10.1158/0008-5472.CAN-05-3018
SUBRAMANIAN MUTHUKKUMAR, TENNORE M. RAMESH, SUBBARAO BONDADA, Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. ,vol. 60, pp. 264- 270 ,(1995) , 10.1097/00007890-199508000-00010
Medhi Wangpaichitr, Chunjing Wu, Min You, M.T. Kuo, Lynn Feun, Theodore Lampidis, Niramol Savaraj, Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. European Journal of Pharmacology. ,vol. 591, pp. 124- 127 ,(2008) , 10.1016/J.EJPHAR.2008.06.028
Luis del Peso, Maribel González-Garcıa, Carmen Page, Román Herrera, Gabriel Nunez, Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt Science. ,vol. 278, pp. 687- 689 ,(1997) , 10.1126/SCIENCE.278.5338.687
Toshiyuki Mori, Hiroshi Okamoto, Naoko Takahashi, Ryuzo Ueda, Takashi Okamoto, Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines FEBS Letters. ,vol. 465, pp. 124- 128 ,(2000) , 10.1016/S0014-5793(99)01726-3
Douglas Hanahan, Robert A Weinberg, The hallmarks of cancer. Cell. ,vol. 100, pp. 57- 70 ,(2000) , 10.1016/S0092-8674(00)81683-9
Marin Marinov, Barbara Fischer, Alexandre Arcaro, Targeting mTOR signaling in lung cancer. Critical Reviews in Oncology Hematology. ,vol. 63, pp. 172- 182 ,(2007) , 10.1016/J.CRITREVONC.2007.04.002
Violeta Serra, Ben Markman, Maurizio Scaltriti, Pieter J.A. Eichhorn, Vanesa Valero, Marta Guzman, Maria Luisa Botero, Elisabeth Llonch, Francesco Atzori, Serena Di Cosimo, Michel Maira, Carlos Garcia-Echeverria, Josep Lluis Parra, Joaquin Arribas, José Baselga, NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Cancer Research. ,vol. 68, pp. 8022- 8030 ,(2008) , 10.1158/0008-5472.CAN-08-1385